Cellebrite Earns $0.17 Per Share, Beats by $0.08, Then Fades to $12.21

Cellebrite DI (NASDAQ:CLBT) reported quarterly EPS of $0.17 against a consensus estimate of $0.09, an $0.08 beat, yet the shares that gapped up on Thursday could not hold the gain. The stock closed Wednesday at $12.70, opened Thursday at $13.37, and last traded at $12.21 — below the pre-announcement close. Volume reached 422,062 shares.

The gap-up was real; the follow-through was not. A company that beats by nearly double the consensus and still trades below its prior close invites a harder look at what the market priced in beforehand, and what it declined to pay for afterward.

What did the quarter actually deliver?

Revenue came in at $149.02 million, ahead of analyst estimates of $145.83 million — a surplus of roughly $3.2 million. The company posted a net margin of 11.43% and return on equity of 15.58%.

Those are solid operating figures. What the announcement did not include, at least in the coverage available, is guidance: no revised revenue range, no full-year EPS outlook, no margin trajectory. An earnings beat without a stated forward path leaves the market to guess, and on Thursday it guessed downward.

How have analysts responded?

The pattern across recent reports is consistent: buy ratings retained, price targets cut.

• JPMorgan cut its target from $20.00 to $16.00 on Friday, August 14, keeping an "overweight" rating.
• Needham & Company lowered its target from $15.00 to $12.50 on Friday, August 14, and kept a "buy" rating.
• Lake Street Capital reduced its objective from $21.00 to $15.00, also on Friday, August 14, with a "buy" rating.
• DA Davidson reiterated a "buy" rating with a $15.00 price target on Tuesday, September 15.
• Weiss Ratings downgraded the stock from "sell (d+)" to "sell (d)" on Thursday, August 27.

Five analysts rate the shares a Buy and one a Sell. MarketBeat.com data shows an average rating of "Moderate Buy" and a consensus price target of $16.70 — roughly 37% above the last traded price. Analysts who cut targets while holding buy ratings are telling two stories at once; the consensus number conceals the direction of the revisions beneath it.

What are insiders doing?

They are selling, and the filings name names.

CRO Marcus Jewell sold 12,562 shares on Friday, August 21, at an average price of $11.24, for a total of $141,196.88. The sale cut his position by 2.86%; he retained 427,128 shares valued at $4,800,918.72.

CFO David Barter sold 12,134 shares on Friday, October 16, at an average price of $11.21, totaling $136,022.14 — a 3.63% reduction that left him with 322,085 shares worth $3,610,572.85. Both transactions appear in SEC disclosures.

In aggregate, insiders sold 56,516 shares worth $636,660 over the last quarter. Insiders own 5.70% of the company. Sales after a beat, executed near $11.20 while the stock trades at $12.21, do not invalidate the quarter — but they do complicate the enthusiasm the gap-up implied.

Where is the institutional money moving?

Institutional investors moved in the opposite direction, and in size, during the first two quarters.

• Nine Ten Capital Management raised its stake by 19.8% in the second quarter, adding 682,933 shares to hold 4,126,808 worth $60,251,000.
• Wellington Management Group grew its holdings by 93.7% in the same quarter, adding 1,475,579 shares to reach 3,049,904 shares worth $44,529,000.
• Renaissance Technologies increased its position by 14.7% in the first quarter, adding 365,700 shares to hold 2,860,639 worth $39,420,000.
• Principal Financial Group lifted its stake by 33.9% in the first quarter, buying 545,334 shares to reach 2,156,166 worth $29,712,000.
• Weiss Asset Management expanded its position by 3,485.3% in the first quarter, adding 1,846,851 shares to hold 1,899,841 worth $26,180,000.

Institutional investors and hedge funds own 45.88% of the stock. Funds bought heavily into the first half; insiders sold through the third quarter. Both positions are on record; neither side has yet been proven wrong.

What do the valuation metrics show?

Cellebrite carries a market capitalization of $3.01 billion, a price-to-earnings ratio of 55.08, a price-to-earnings-growth ratio of 1.94, and a beta of 1.06. The 50-day moving average sits at $11.62 and the 200-day at $13.27. The last traded price of $12.21 sits between the two — above the short-term trend, below the long-term one. A 55 multiple leaves little room for a miss.

Cellebrite develops digital intelligence software that lets organizations access, collect, preserve and analyze digital evidence from mobile devices, computers and cloud sources. Its products include the UFED extraction platform, Physical Analyzer, and the Pathfinder and Guardian analytics and case-management tools. Its customers are law enforcement, public safety, intelligence and defense agencies, plus private-sector organizations.

A $0.08 beat, $636,660 of insider sales and a $16.70 consensus target: the quarter delivered, the filings deducted, and the tape split the difference.